A Novel Europium Chelate Coated Nanosphere for Time-Resolved Fluorescence Immunoassay

Yifeng Shen¹,³, Shaohan Xu², Donghua He³*

¹ Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, China, ² The First Affiliate Hospital of Fujian Medical University, Fuzhou, Fujian, China, ³ Triplex International Bioscience (China) CO., Ltd., Xiamen, Fujian, China

* hdh@tibchina.com

Abstract

A novel europium ligand 2, 2', 2'', 2'''-(4, 7-diphenyl-1, 10-phenanthroline-2, 9-diyl) bis (methylene) bis (azanetriyl) tetra acetic acid (BC-EDTA) was synthesized and characterized. It shows an emission spectrum peak at 610 nm when it is excited at 360 nm, with a large Stock shift (250 nm). It is covalently coated on the surface of a bare silica nanosphere containing free amino groups, using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-Hydroxysuccinimide. We also observed an interesting phenomenon that when BC-EDTA is labeled with a silica nanosphere, the chelate shows different excitation spectrum peaks of about 295 nm. We speculate that the carboxyl has a significant influence on its excitation spectrum. The BC-EDTA/Eu³⁺ coated nanosphere could be used as a fluorescent probe for time-resolved fluorescence immunoassay. We labeled the antibody with the fluorescent nanosphere to develop a nanosphere based hepatitis B surface antigen as a time-resolved fluorescence immunoassay reagent, which is very easy to operate and eliminates potential contamination of Eu³⁺ contained in the environment. The analytical and functional sensitivities are 0.0037 μg/L and 0.08 μg/L (S/N ≥ 2.0) respectively. The detection range is 0.08-166.67 μg/L, which is much wider than that of ELISA (0.2-5 μg/L). It is comparable to the commercial dissociation-enhanced lanthanide fluoro-immunoassay system (DELFIA) reagents (0.2-145μg/L). We propose that it can fulfill clinical applications.

Introduction

Multiple studies reported that lanthanide and its chelate can be applied in time-resolved fluorescence immunoassay (TrFIA)[1, 2]. It is widely used in clinical immunoassay, such as in DELFIA reagents (Perkinelmer Inc.). Europium and its chelate have many features that make them suitable for TrFIA, the maximum excitation wavelength of Eu³⁺ fluorescent complexes is in the UV region and the emission maximum is about 610 nm, which is ion-specific. This large Stokes shift can avoid the interference of excitation light. The emission band of Eu³⁺ fluorescent complexes is very narrow, with the full width at half maximum (FWHM) being about 10
The most important feature of the complexes is they have very long fluorescence lifetimes ranging from 1 μs to over 2 ms, which are longer than background fluorescence. These characteristics of Eu³⁺ fluorescent complexes can be used to detect biomolecules using time-resolved fluorometry with high sensitivity[3].

Dual-functional europium chelate isothiocyanatophenyl-EDTA-Eu³⁺ and N¹-(p-isothiocyanatobenzyl) diethylenetriamine-N¹,N²,N³,N⁴—teta acetic acid-Eu³⁺ is used in the dissociation-enhanced lanthanide fluoroimmunoassay system (DELFIA), which has been commercially available for decades. These chelates are not fluorescent; they only can bind Eu³⁺ with antibodies. After immunological reaction, Eu³⁺ dissociates in acid buffer and combines with other fluorescent ligands, such as β-naphthoyltrifluoroacetone (β-NTA), resulting in fluorescent complexes that emit strong fluorescence[4]. Although the DELFIA system has a high sensitivity, it is vulnerable to Eu³⁺ contamination. This is because the excess ligands can be contaminated by the Eu³⁺ contained in the environment leading to a high background level. Furthermore, the fluorescent signal is not bound to the antibody directly[4, 5].

In the CyberFluor system, europium ligand 4, 7-bis (chlorosulfophenyl)-1, 10-phenanthroline-2, 9-dicarboxylic acid (BCPDA) was directly labeled with protein[6]. In this system, the background is low because no excess ligands exist in the solution. However because BCPDA has only 4 chelate sites, the fluorescence of the chelate is weaker than the β-NTA-Eu³⁺ complex contained in the DELFIA system[7]. When BBCAP chelates with Eu³⁺, it has an emission maximum at 610 nm when excited with UV light of 280 nm[8]. Jingli Yuan and Kazuko Matsu-moto first synthesized 4, 4-bis (1, 1, 2, 2, 3, 3-heptafluoro-4, 6-hexanedion-6-yl) chlorosulfo-terphenyl (BHHCT), which is a kind of tetradentate β-diketonate-europium ligand. It shows an emission at 610 nm when excited at 330 nm[9]. The usage of BHHCT is limited because it can only dissolve in organic solutions and it has poor solubility in H₂O[9]. Peng Lin et al. synthesized BBCAP a bis-functional ligand, and applied it in TrFIA[10]. These ligands indicate that phenanthroline is suitable for efficient transfer of energy from the ligand to Eu³⁺ with a high fluorescence quantum yield.

Many studies reported that using a multiple-label system is an effective approach to amplifying signals of existing chelates[11–13]. In multiple label systems, streptavidin[7] and polymeric compounds[11, 14] are used as the molecular carriers. The great number of fluorescent chelates carried by a single carrier can serve as a probe to conjugate with an antibody for TrFIA, yielding a high sensitivity. A polystyrene nanosphere contains europium chelates synthesized as a probe for TrFIA, which can provide a very high sensitivity. The polystyrene nanosphere was conjugated with streptavidin or antibodies to detect prostate-specific antigen[15, 16], and thyroid stimulating hormone[17] in an easy-to-operate system that provided very high sensitivity. A silica nanosphere which contains Eu³⁺ or Tb³⁺ chelates is another choice for a TrFIA probe[18–20]. Silica nanospheres containing europium and terbium chelates were easily synthesized; fluorescence chelates can be physically doped or covalently conjugated with a silica nanosphere. These nanospheres containing europium chelates with multiple chelate sites contributed to high sensitivity TrFIA reagents. Furthermore, because there are no surplus ligands, its background is much lower than that of DELFIA reagents.

In this paper, we report that a novel europium ligand contains 8 chelate sites, namely 2, 2', 2", 2"'- (4, 7-diphenyl-1, 10-phenanthroline-2, 9-diyi) bis (methylene) bis (azanetriyl) tetra acetic acid (BC-EDTA, Fig 1). It forms a stable complex with Eu³⁺, and emits strong fluorescence when excited with UV light, at 360 nm. It can be easily dissolved in H₂O. It was covalently coated onto the surface of a preformed bare silica nanosphere with free amino groups, resulting in a fluorescent nanosphere. Biomarkers such as antibodies can be labeled with such nanospheres to form probes. We developed a nanosphere based time-resolved fluorescence immunoassay (TrFIA) to detect surface antigen of hepatitis B virus (HBsAg), with the analytical
and functional sensitivities at 0.0037 μg/L and 0.08 μg/L (S/N > 2.0), respectively. The detection range was 0.08–166.67 μg/L, which is much wider than ELISA (0.2–5 μg/L), and is comparable to commercial dissociation-enhanced lanthanide fluoroimmunoassay system (DELFIA) reagents. Additionally, the nanosphere based TrFIA is much easier to manipulate than DELFIA reagents and eliminates potential Eu³⁺ contamination.

Methods

Synthesis of BC-EDTA

BC-EDTA was synthesized according to the following scheme (Fig 1), the synthesis procedure was illuminated by the synthesis of BCPDA [6] and BBCAP [10]. Ethanol and acetonitrile must be distilled to remove the surplus water.

(1) Materials and Instruments. 1, 4-dioxane aqueous, kieselguhr, anhydrous ethanol, anhydrous acetonitrile, sodium carbonate, acetone, sodium hydroxide, and hydrochloric acid were purchased from SCRC. Bathocuproine (BC), selenium dioxide, sodium borohydride, and hydrobromic acid was purchased from ABCR. Diethyl iminodiacetat was purchased from Sigma. Anhydrous ethanol was distilled from magnesium and iodine. Anhydrous acetonitrile was distilled from phosphorus pentoxide.

¹H NMR spectra were recorded on Varian Unity+ 500M Hz. ¹H NMR spectra were registered in D₂O, and chemical shifts are expressed in parts per million (δ) relative to internal
Me₄Si. IR spectra were recorded on a Nicolet Avatar 330 FTIR spectrophotometer. Mass spectra were recorded by Bruke BioTOF-Q. UV spectra were recorded on a Persee TU-1900 ultraviolet and visible spectrophotometer.

(2) Preparation of BC-CHO. Bathocuproin (BC) (0.5 g, 1.39mmol) and selenium dioxide (0.75 g, 6.76 mmol) were gradually added to 50 mL stirring 1, 4-dioxane aqueous solution (4% H₂O) and the mixture was refluxed for 2 hours at 101°C. The mixture was filtered by kieselguhr while still hot and then mixed with water and stored at 2~8°C for 1 hour. The precipitate was separated from the cold filtrate as brown crystals with a yield of 79.8% (0.43 g). MS (ESI): 389.2 m/z (M+H+).

(3) Preparation of BC-MeOH. BC-CHO (0.4 g, 1.03 mmol) and aqueous sodium borohydride (0.06 g, 1.59 mmol) were gradually added to 40 mL stirring anhydrous ethanol and refluxed for 2 hours at 100°C. The mixture was then filtered, and the resulting filtrate was mixed with water and stored at 2~8°C for 1 hour. The precipitate was separated from the cold filtrate as a pink powder with a yield of 82.7% (0.45 g). MS (ESI): 415.5 m/z (M+Na+).

(4) Preparation of BC-BrCH₂. BC-MeOH (0.4 g, 1.02 mmol) was added to 12 mL hydrobromic acid (48%) and refluxed for 2 hours. The mixture was cooled in ice water and then aqueous sodium carbonate was gradually added until the precipitate was fully formed. 30 mL ethanol was then added and the mixture was placed in a boiling water bath to completely dissolve the precipitate. The filtrate was collected and mixed with water, then stored at 2~8°C for 1 hour. A yellow powder of BC-BrCH₂ was then collected and dried with a yield of 45.9% (0.33 g). MS (ESI): 519.2 m/z (M+H+).

(5) Preparation of BC-EDTA ester. BC-BrCH₂ (0.3 g, 0.58 mmol) and sodium carbonate (0.45 g, 4.25 mmol) were combined in stirring 20 mL anhydrous acetonitrile and diethyl imino-diacetate (210 μL, 1.17 mmol) was gradually added. Then the mixture was stirred in darkness in a nitrogenous atmosphere to avoid photobleaching and oxidation. This reaction took place at room temperature for 24 hours. This filtrate was then collected and vacuum-dried. A brown solid of BC-EDTA ester was obtained with a yield of 53.97% (0.55 g). MS (ESI): 758.1 m/z (M+Na+).

(6) Preparation of BC-EDTA. 4 mL sodium hydroxide solution (1 mol/L) was gradually added to a solution of 0.5 g (0.68 mmol) BC-EDTA ester and 8 mL acetone. After stirring for 2 hours in darkness to avoid photobleaching, the mixture was neutralized with hydrochloric acid. The liquid was then vacuum-dried, washed with acetone 3 times, and then recrystallized 3 times from water. A brown powder of BC-EDTA was obtained with a yield of 53.2% (0.46 g). MS (ESI): 623.3 m/z (M+H+). IR (film) νmax: 3431, 2922, 1631, 1602, 1496, 1403, 1332, 1263 cm⁻¹; ¹H NMR (500 MHz, D₂O) δ0 M): 3.295 ppm (s, 8H), 4.094 ppm (s, 4H), 7.356 (m, 14H) ppm; UV spectrum: λmax = 360nm (Fig 2).

Preparation of Silica Nanosphere and Labeling of BC-EDTA

(1) Preparation of Bare Silica Nanosphere. The method of preparation of the nanoscale bare silica nanosphere was described by Bagwe RP, Santra S[21, 22]. Amino groups were introduced to the surface of particles by (3-Aminopropyl) trimethoxysilane (APTMS) [23]. A15 mg bare nanosphere was suspended in 1 mL ethanol, then 3 μL APTMS was added into the suspension, and stirred for 2 hours at room temperature, then washed with acetone 3 times, and then was suspended in 1 mL 0.05 mol/L phosphate buffer (pH6.8).

(2) Preparation of BC-EDTA/Eu³⁺ conjugated Silica Nanosphere. BC-EDTA/Eu³⁺ was conjugated with the silica nanosphere by the following scheme (Fig 3) [24].

BC-EDTA (3.4 mg), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) (3.9 mg), and N-Hydroxysuccinimide (NHS) (0.4 mg) were dissolved in 200 μL 0.05
mmol/L phosphate buffer (pH 6.8), and left to react for 30 minutes in darkness. This solution was then mixed with the nanosphere described above. The nanosphere was washed and suspended in 1 mL 0.01 mol/L Tris-HCl (pH 7.8). 200 μL EuCl₃ (0.04 mol/L) was added to the nanosphere suspension and left to react for 20 minutes in darkness. It was washed in 1 mL 0.01 mol/L Tris-HCl (pH 7.8) 3 times and then suspended in 1 mL ethanol. 20μL tetraethylsilane (TEOS) was added to the suspension, stirred in darkness for 2 hours, and then resuspended in 1mL ethanol. 3 μL APTMS was then added to the solution, stirred in darkness for 2 more hours, then placed in a metal bath at 69°C for 5 minutes and washed in ethanol 3 times.

The procedure was repeated 5 times completely, and the BC-EDTA/Eu³⁺-nanosphere was suspended and stored in ethanol.

**Labeling of antibody with BC-EDTA/Eu³⁺-nanosphere**

An antibody (anti HBsAg monoclonal antibody IgG, 5#) was conjugated with the BC-EDTA/Eu³⁺ nanosphere by oxidized-dextran (Fig 4) [24]. 1 mL 0.5mol/L NaIO₄ was mixed with 50 mg/
mL dextran and left to react at room temperature for 2 hours. The mixture was then dialyzed in ice water. 2 mg BC-EDTA/Eu (III)-nanosphere was washed and suspended in 0.025mol/L carbonate buffer (pH 9.6) and mixed with oxidized dextran, left to react in darkness at 37°C for 3 hours, then washed and suspended in 0.025mol/L carbonate buffer (pH 9.6). 0.2 mg antibody was dialyzed in 0.025mol/L carbonate buffer (pH9.6), mixed with the above nanosphere, left to react in darkness at 2~8°C for 12 hours, and then NaBH₃CN was added to the concentration of 0.005mol/L. BSA (10mg/mL) was used as the blocking agent. The mixture was washed and suspended in 0.01mL Tris-HCl (pH 7.8), and stored in darkness at 2~8°C.

Unspecific conjugation of antibody labeled BC-EDTA/Eu³⁺-nanosphere

An antibody labeled as BC-EDTA/Eu³⁺-nanosphere was diluted to the concentration of 0.002%, 0.001%, and 0.0005%. The 100\(\mu\)L diluted antibody labeled as BC-EDTA/Eu³⁺-nanosphere was added onto a capture antibody-coated microwell plate (anti HBsAg monoclonal antibody IgG, 2#). The plate was incubated at 37°C for 60 min, and washed 5 times with washing buffer, then it was subjected to TRF measurement (Perkinelmer Victor X).

Labeling of antibody with BC-EDTA/Eu³⁺-nanosphere

The antibody labeled as BC-EDTA/Eu³⁺-nanosphere was diluted to concentrations of 0.002%, 0.001%, 0.0005%, and 0.00025%, and 0.000125%. The 100\(\mu\)L diluted antibody labeled as BC-EDTA/Eu³⁺-nanosphere was added onto an antigen-coated microwell plate (recombinant HBsAg, 0.4\(\mu\)g/mL, 0.2\(\mu\)g/mL). The plate was incubated at 37°C for 60 minutes, and washed 5 times with washing buffer, and then was subjected to TRF measurement (Perkinelmer Victor X).

Measurement of HBsAg

A double antibody sandwich method was applied for HBsAg TrIFA (Fig 5).

A capture antibody (anti HBsAg antibody IgG, 2#, 5 \(\mu\)g/mL in 0.02 mol/L phosphate buffer, pH7.4) was physically coated on the white plastic microwell plate (50 \(\mu\)L/well), and the microwell plate was blocked by 2% BSA. 100\(\mu\)L of standard solution for calibration or serum sample was added to each well, and incubated at 37°C for 60 min, then washed 3 times by washing buffer (0.02mol/L phosphate buffer, pH7.4, 0.2% tween-20). Then 100\(\mu\)L of labeling antibody conjugated BC-EDTA/Eu³⁺-nanosphere (diluted 1000-fold) was added to each well. The plate was incubated at 37°C for 60 min, washed 5 times with washing buffer, and then was subjected to TRF measurement (Perkinelmer Victor X).

We still did a contrast test with commercial HBsAg DELFIA reagents (Sym-bio lifescience Inc., China). In total, 230 human serum samples were detected by BC-EDTA/Eu³⁺-nanosphere based TrFIA and DELFIA reagents. A pair T test was used to verify correlation between BC-EDTA/Eu³⁺-nanosphere based TrFIA and DELFIA reagents. We also subjected HBsAg reference panel to BC-EDTA/Eu³⁺-nanosphere based TrFIA for the validation study.
Human Samples

Human blood samples were collected by vacuum tube from hospital patients, serum was separated by centrifugation. Blood samples used in this study were surplus of those collected for routine clinical tests from clinical laboratories. We did not take special samples for this study.

Ethics Statement

The study was specifically approved by the Medical Ethics Committee of Fujian Medical University and a written informed consent was signed for each participant.

Results

Preparation of BC-EDTA conjugated silica nanosphere

Prepared bare silica nanosphere is spherical and uniform in size (55±5nm in diameter, Fig 6). After APTMS treatment, the existence of amino groups on the surface was confirmed by the observation of salicylaldehyde-mediated yellow color (data not shown). Coating was done in multiple rounds to increase the overall chelate loading. With BC-EDTA/Eu³⁺, maximal loading was achieved after 5 rounds of coating (Fig 7). The fluorescent nanosphere showed light aggregation in ethanol, and can be easily dispersed by ultrasonic treatment.

The BC-EDTA/Eu³⁺ coated nanosphere (Fig 8) didn’t show significant difference in size and shape compared with the bare silica nanosphere (Fig 6). We found an interesting phenomenon where the maxima excitation wavelength of a BC-EDTA nanosphere is shortened compared with a bare one, and peaks at about 295 nm (Fig 9). We also found that when BC-EDTA reacted with EDC and NHS, its excitation spectrum showed the same difference. It is speculated that carboxyl has an important influence on its excitation. The fluorescence lifetimes of free and coated BC-EDTA/Eu³⁺ were 0.48 and 0.51 ms, respectively.
Unspecific conjugation of antibody labeled BC-EDTA/Eu³⁺-nanosphere

Overall, the unspecific conjugation rate of an antibody labeled BC-EDTA/Eu³⁺-nanosphere and an unlabeled BC-EDTA/Eu³⁺-nanosphere is less than 0.10% (Table 1). This means that there is no unspecific conjugation between an antibody coated microwell plate and an antibody labeled BC-EDTA/Eu³⁺-nanosphere, neither between the antibody coated microwell plate and the unlabeled BC-EDTA/Eu³⁺-nanosphere.

Fig 6. TEM of bare silica nanosphere.

doi:10.1371/journal.pone.0129689.g006

Unspecific conjugation of antibody labeled BC-EDTA/Eu³⁺-nanosphere

Overall, the unspecific conjugation rate of an antibody labeled BC-EDTA/Eu³⁺-nanosphere and an unlabeled BC-EDTA/Eu³⁺-nanosphere is less than 0.10% (Table 1). This means that there is no unspecific conjugation between an antibody coated microwell plate and an antibody labeled BC-EDTA/Eu³⁺-nanosphere, neither between the antibody coated microwell plate and the unlabeled BC-EDTA/Eu³⁺-nanosphere.

Fig 7. Relationship between fluorescence intensity of nanosphere and coating times. BC-EDTA/Eu³⁺-nanosphere was diluted in 0.05 mol/L carbonate buffer, pH9.5, with the concentration of 0.01%.

doi:10.1371/journal.pone.0129689.g007
Labeling of antibody with BC-EDTA/Eu³⁺-nanosphere

Overall, the specific conjugation rate of an antibody with BC-EDTA/Eu³⁺-nanosphere was no less than 21997.98% (Table 2). This means that the antibody was successfully conjugated with BC-EDTA/Eu³⁺-nanosphere. It further indicates that the antibody still keeps its biological activity, and that the antibody can recognize and binds with HBsAg.

**Fig 9.** Excitation and Emission spectra of BC-EDTA/Eu³⁺ (A) and BC-EDTA/Eu³⁺-nanosphere (B). (A) The concentration of BC-EDTA/Eu³⁺ is 10⁻³mol/L. The buffer was 0.05 mol/L carbonate buffer, pH9.5. (B) The concentration of BC-EDTA/Eu³⁺-nanosphere is 0.005%. The buffer was 0.05 mol/L carbonate buffer, pH9.5.

doi:10.1371/journal.pone.0129689.g009
Measurement of HBsAg

The analytical sensitivity was 0.0037 μg/L, defined by 3 SD of zero calibrator, functional sensitivity was 0.08 μg/L, which was equivalent to the calibrator with S/N/C21 = 2.0 (Table 3). The analytical precision of determining the HBsAg in human serum ranged from 2.21% to 6.14% (Table 4). The analytical recovery rate ranged from 89.62% to 128.00% (Table 5).

The linear range of the nanosphere-based TrFIA of HBsAg was 0.08–166.67 μg/L (Fig 10) which was superior to commercial DELFIA reagents (0.2–145ng/mL). In contrast, the linear range of ELISA was 0.2–5.0 μg/L with a detection limit of 0.2 μg/L.

Table 1. Unspecific conjugation of antibody labeled BC-EDTA/Eu³⁺-nanosphere, unlabeled BC-EDTA/Eu³⁺-nanosphere to antibody coated microwell plate.

| Nanosphere concentration | antibody labeled BC-EDTA/Eu³⁺-nanosphere | unlabeled BC-EDTA/Eu³⁺-nanosphere |
|--------------------------|------------------------------------------|-----------------------------------|
| Counts¹                 | CV (%)                                   | Unspecific conjugation (%)         |
| CV (%)                  | Unspecific conjugation (%)               |
| 0.002%                  | 310.9                                    | 1.94                              | 0.29 |
| 0.001%                  | 310.3                                    | 2.18                              | 0.03 |
| 0.0005%                 | 307.5                                    | 2.08                              | 0.10 |

Table 2. Specific conjugation of antibody labeled BC-EDTA/Eu³⁺-nanosphere to HBsAg coated mircowell plate.

| Nanosphere concentration | 0.4μg/mL HBsAg coated microwell plate | 0.2μg/mL HBsAg coated microwell plate |
|--------------------------|---------------------------------------|---------------------------------------|
| Counts¹                 | CV (%)                                | Specific conjugation (%)               |
| Specific conjugation (%)|
| 0.002%                  | 15877191                              | 3.30                                  | 5138249.51 |
| 0.001%                  | 7498215.8                              | 2.27                                  | 2426607.06 |
| 0.0005%                 | 3467750.4                              | 2.42                                  | 1122249.32 |
| 0.00025%                | 1719485                                | 2.50                                  | 577963.11  |
| 0.000125%               | 845897.6                               | 2.14                                  | 273753.27  |

Table 3. Functional sensitivity of BC-EDTA/Eu³⁺-nanosphere.

| Concentration of HBsAg (μg/L) | Counts¹ | S/N |
|-------------------------------|---------|-----|
| 1.25                          | 12408.667 | 19.10 |
| 0.63                          | 8504.667  | 13.09 |
| 0.31                          | 3175.333  | 4.89 |
| 0.20                          | 2460.333  | 3.79 |
| 0.16                          | 2077.000  | 3.20 |
| 0.08                          | 1394.000  | 2.15 |
| 0.04                          | 1031.000  | 1.59 |
| 0.02                          | 865.667   | 1.33 |
| 0.01                          | 695.667   | 1.07 |
| 0.00                          | 649.667   | 1.00 |

¹ Mean value of net fluorescence counts (n = 10).
In the contrast study, 230 human serum samples were detected by the BC-EDTA/Eu³⁺-nanosphere based TrFIA reagent and by the DELFIA reagent. Both of these two methods’ cut-off value was defined as \( \geq 0.2 \mu g/L \). Coincidence rate of qualitative analyses of these two methods is 100%. For the 119 positive samples, the correlation coefficient between the BC-EDTA/Eu³⁺-nanosphere based TrFIA and the commercial DELFIA reagents was \( r = 0.98262 \) (Fig 11), results showed that there is a great correlation between these two methods. Result of the HBsAg reference panel also meets our expectation (data not shown).

### Conclusion and Discussion

Our results indicate that the novel europium ligand BC-EDTA is suitable for TrFIA as demonstrated by its excellent water solubility. ESI-MS, Infrared Absorption Spectra, Ultraviolet-

![Fig 10. Calibration curves for HBsAg.](doi:10.1371/journal.pone.0129689.g010)
Visible (UV) Absorption Spectrum, and H¹NMR results all showed successful synthesis of the ligand.

BC-EDTA/Eu³⁺ was covalently coated onto the surface of a silica nanosphere. Transmission electron microscope images showed that the fluorescent nanosphere had no significant visual difference compared with bare silica nanosphere. Taking advantage of the signal amplification effect of the nanosphere, the BC-EDTA/Eu³⁺-nanosphere emitted intense fluorescence when excited by ultraviolet light. The fluorescence lifetime of the BC-EDTA/Eu³⁺-nanosphere is a marginally longer than the free one, which suggests that immobilization can improve the fluorescence lifetime of chelate. Maximum excitation wavelength changed significantly when BC-EDTA reacted with EDC and NHS. This suggests that the phenomenon of maximum excitation shift can be applied in other applications, such as transfer wavelength detection. We plan to explore this area in the future.

Free amino groups on the surface of the BC-EDTA/Eu³⁺-nanosphere makes antibodies can covalently conjugated with the nanosphere. All of these characteristics showed that the BC-EDTA/Eu³⁺-nanosphere can be applied in TrFIA. The procedure for the synthesis of BC-EDTA described here is simple, and the process of preparing a fluorescent nanosphere and an antibody-fluorescent nanosphere complex is simple and easily controllable. The complex can be purified by centrifugation, which is also easy to operate and control.

The antibody-fluorescent nanosphere complex solution emitted an intense and stable signal, and can be applied in the double antibody sandwich method to detect HBsAg. The results showed that the nanosphere based TrFIA system has a high sensitivity (0.0037μg/L), wide linear range (0.08–166.67μg/L, r = 0.99482), high recovery rate (89.62–128.00%), and low CV (2.21–6.14%). Benefits of nanosphere based TrFIA include good correlation with commercial DELFIA reagents, ease of use, and decreased Eu³⁺ contamination from the environment. Because of the low background, the BC-EDTA/Eu³⁺-nanosphere based TrFIA has higher sensitivity than the commercial DELFIA reagents. Demonstrated that the novel ligand BC-EDTA and the fluorescent nanosphere described here had very good application prospects in clinical examinations.
Acknowledgments

We thank Jianliang Ye for his excellent work in characterization of BC-EDTA, including H NMR, ESI-MS and IR. We thank Ping Chen for her help in transmission electronic microscope imaging. We thank Dingrong Yi for her significant contribution in editing.

Author Contributions

Conceived and designed the experiments: YS DH. Performed the experiments: YS SX. Analyzed the data: YS SX DH. Contributed reagents/materials/analysis tools: YS DH. Wrote the paper: YS DH.

References

1. Erkki S, Iikka H. Fluoroimmunoassay: present status and key problems. Clinical chemistry. 1979; 25(3):353–61. PMID: 400437
2. Iikka H. Fluoroimmunoassays and immunofluorometric assays. Clinical chemistry. 1985; 33(5):359–70.
3. Soini E, Lövgren T, Reimer CB. Time-Resolved Fluorescence of Lanthanide Probes and Applications in Biotechnology. CRC Critical Reviews in Analytical Chemistry. 1987; 18(2):105–54. doi: 10.1080/10408348708542802
4. Diamandis EP. Immunoassays with time-resolved fluorescence spectroscopy: principles and applications. Clinical Biochemistry. 1988; 21(3):139–50. PMID: 3292080
5. Mathis G. Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clinical chemistry. 1993; 39(9):1953–9. PMID: 8375081
6. Evangelista RA, Pollak A, Allore B, Templeton AF, Morton RC, Diamandis EP. A new europium chelate for protein labelling and time-resolved fluorometric applications. Clinical Biochemistry. 1988; 21(3):173–8. PMID: 3390907
7. Morton RC, Diamandis EP. Streptavidin-Based Macromolecular Complex Labeled with a Europium Chelator Suitable for Time-Resolved Fluorescence Immunoassay Applications. Analytical Chemistry. 1990; 62(17):1814–5.
8. Iikka H. Lanthanides as probes for time-resolved fluorometric immunoassays. Scandinavian Journal of Clinical & Laboratory Investigation. 1988; 48(5):389–99. PMID: 3060984
9. Yuan J, Matsumoto K. A New Tetradentate β-Diketonate-Europium Chelate That Can Be Covalently Bound to Proteins for Time-Resolved Fluoroimmunoassay. Analytical Chemistry. 1998; 70(3):596–601. PMID: 9470488
10. Lin P, Zheng H, Zhu Q, Xu J. A New Fluorimetric Reagent for Highly Selective and Sensitive Determination of Terbium Ion. Microchimica Acta. 2002; 140:125–9.
11. Scorilas A, Bjartell A, Lilja H, Moller C, Diamandis EP. Streptavidin-polyvinylamine conjugates labeled with a europium chelate: applications in immunoassay, immunohistochemistry, and microarrays. Clinical chemistry. 2000; 46(9):1450–5. PMID: 10973889
12. Diamandis EP. Signal Amplification in Time-resolved Fluorometry. Clinical chemistry. 2001; 47(3):380–1. PMID: 11238286
13. Diamandis EP. Multiple labeling and time-resolvable fluorophores. Clinical chemistry. 1991; 37(9):1486–91. PMID: 1716533
14. Scorilas A, Diamandis EP. Polyvinylamine-streptavidin complexes labeled with a europium chelator: a novel detection reagent for solid-phase time resolved fluorometric applications. Clinical Biochemistry. 2000; 33(5):345–50. PMID: 11018685
15. Härma H, Soukka T, Lövgren T. Europium nanoparticles and time-resolved fluorescence for ultrasensitive detection of prostate-specific antigen. Clinical chemistry. 2001; 47(3):561–8. PMID: 11238312
16. Huhtinen P, Soukka T, Lövgren T, Härma H. Immunoassay of total prostate-specific antigen using europium(III) nanoparticle labels and streptavidin-biotin technology. Journal of Immunological Methods. 2004; 294(1–2):111–22. doi: 10.1016/j.jim.2004.09.002 PMID: 15604021.
17. Huhtinen P, Pelkkikangas A-M, Jaakohuhta S, Lövgren T, Härma H. Quantitative, rapid europium(III) nanoparticle-label-based all-in-one dry-reagent immunoassay for thyroid-stimulating hormone. Clinical chemistry. 2004; 50(10):1935–6. PMID: 15484330
18. Tan M, Ye Z, Wang G, Yua J. Preparation and Time-Resolved Fluorometric Application of Luminescent Europium Nanoparticles. Chemistry of Materials. 2004; 16(12):2494–8.
19. Tan M, Wang G, Hai X, Ye Z, Yuan J. Development of functionalized fluorescent europium nanoparticles for biolabeling and time-resolved fluorometric applications. Journal of Materials Chemistry. 2004; 14(19):2896–901. doi:10.1039/b407535h

20. Huhtinen P, Kivelä M, Kuronen O, Hagren V, Takalo H, Tenhu H, et al. Synthesis, characterization, and application of Eu (III), Tb (III), Sm(III), and Dy(III) lanthanide chelate nanoparticle labels. Analytical Chemistry. 2005; 77(8):2463–8. PMID: 15828781

21. Bagwe RP, Yang C, Hilliard LR, Tan W. Optimization of dye-doped silica nanoparticles prepared using a reverse microemulsion method. Langmuir. 2004; 2004(20):19.

22. Santra S, Wang K, Tapec R, Tan W. Development of novel dye-doped silica nanoparticles for biomarker application. Journal of biomedical optics. 2001; 6(2):160–6. doi:10.1117/1.1353590 PMID: 11375725.

23. Waddell TG, Leyden DE, DeBello MT. The Nature of Organosilane to Silica-Surface Bonding. J Am Chem Soc. 1981; 103(18):5303–6.

24. Xu Y, Li Q. Multiple fluorescent labeling of silica nanoparticles with lanthanide chelates for highly sensitive time-resolved immunofluorometric assays. Clinical chemistry. 2007; 53(8):1503–10. doi:10.1373/clinchem.2006.078485 PMID: 17556649.